Atopic Dermatitis/Skin Diseases
Subcutaneous lanadelumab, a monoclonal antibody drug, for 26 weeks significantly reduces attack rates of hereditary angioedema, according to data published in JAMA.
The results of the trial supported the FDA approval of lanadelumab (Takhzyro, Dyax Corp.) for hereditary angioedema, a rare, potentially life-threatening disorder caused by genetic mutations associated with decreased levels of, or dysfunctional, C1 inhibitor protein.
This activity is supported by an educational grant from DBV Technologies.
View past polls »
Search Healio's robust listing of national and international medical meetings.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2018 Healio All Rights Reserved.